CO2022006708A2 - Anticuerpos trem2 y usos de estos - Google Patents
Anticuerpos trem2 y usos de estosInfo
- Publication number
- CO2022006708A2 CO2022006708A2 CONC2022/0006708A CO2022006708A CO2022006708A2 CO 2022006708 A2 CO2022006708 A2 CO 2022006708A2 CO 2022006708 A CO2022006708 A CO 2022006708A CO 2022006708 A2 CO2022006708 A2 CO 2022006708A2
- Authority
- CO
- Colombia
- Prior art keywords
- trem2 antibodies
- trem2
- antibodies
- diseases
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a anticuerpos TREM2 y usos de estos para tratar enfermedades tales como enfermedades neurodegenerativas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962939097P | 2019-11-22 | 2019-11-22 | |
PCT/US2020/060663 WO2021101823A1 (en) | 2019-11-22 | 2020-11-16 | Trem2 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022006708A2 true CO2022006708A2 (es) | 2022-05-31 |
Family
ID=73790267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0006708A CO2022006708A2 (es) | 2019-11-22 | 2022-05-20 | Anticuerpos trem2 y usos de estos |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220281975A1 (es) |
EP (1) | EP4061842A1 (es) |
JP (1) | JP7368624B2 (es) |
KR (1) | KR20220084152A (es) |
CN (1) | CN114667295B (es) |
AU (1) | AU2020387380A1 (es) |
BR (1) | BR112022007944A2 (es) |
CA (1) | CA3159055A1 (es) |
CO (1) | CO2022006708A2 (es) |
CR (1) | CR20220228A (es) |
DO (1) | DOP2022000104A (es) |
EC (1) | ECSP22041169A (es) |
IL (1) | IL293018A (es) |
JO (1) | JOP20220119A1 (es) |
MX (1) | MX2022006145A (es) |
PE (1) | PE20221337A1 (es) |
WO (1) | WO2021101823A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL279606B (en) * | 2014-08-08 | 2022-08-01 | Alector Llc | Anti-trem2 antibodies and methods of using them |
CA2997960A1 (en) * | 2015-10-06 | 2017-04-13 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
WO2018015573A2 (en) * | 2016-07-22 | 2018-01-25 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Trem2 cleavage modulators and uses thereof |
PE20200148A1 (es) * | 2017-08-03 | 2020-01-17 | Alector Llc | Anticuerpos anti-trem2 y metodos para utilizarlos |
JP7403441B2 (ja) * | 2017-09-14 | 2023-12-22 | デナリ セラピューティクス インコーポレイテッド | 抗trem2抗体及びその使用方法 |
KR20200097765A (ko) * | 2017-12-12 | 2020-08-19 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem2 항체 및 관련 방법 |
-
2020
- 2020-11-16 WO PCT/US2020/060663 patent/WO2021101823A1/en active Application Filing
- 2020-11-16 BR BR112022007944A patent/BR112022007944A2/pt not_active Application Discontinuation
- 2020-11-16 CR CR20220228A patent/CR20220228A/es unknown
- 2020-11-16 JP JP2022529507A patent/JP7368624B2/ja active Active
- 2020-11-16 IL IL293018A patent/IL293018A/en unknown
- 2020-11-16 MX MX2022006145A patent/MX2022006145A/es unknown
- 2020-11-16 PE PE2022000821A patent/PE20221337A1/es unknown
- 2020-11-16 JO JOP/2022/0119A patent/JOP20220119A1/ar unknown
- 2020-11-16 EP EP20821525.1A patent/EP4061842A1/en active Pending
- 2020-11-16 CA CA3159055A patent/CA3159055A1/en active Pending
- 2020-11-16 KR KR1020227016708A patent/KR20220084152A/ko active Search and Examination
- 2020-11-16 AU AU2020387380A patent/AU2020387380A1/en active Pending
- 2020-11-16 CN CN202080079451.2A patent/CN114667295B/zh active Active
-
2022
- 2022-05-05 US US17/737,439 patent/US20220281975A1/en active Pending
- 2022-05-19 DO DO2022000104A patent/DOP2022000104A/es unknown
- 2022-05-20 CO CONC2022/0006708A patent/CO2022006708A2/es unknown
- 2022-05-20 EC ECSENADI202241169A patent/ECSP22041169A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20221337A1 (es) | 2022-09-13 |
BR112022007944A2 (pt) | 2022-07-12 |
CN114667295A (zh) | 2022-06-24 |
JOP20220119A1 (ar) | 2023-01-30 |
US20220281975A1 (en) | 2022-09-08 |
JP2023502460A (ja) | 2023-01-24 |
ECSP22041169A (es) | 2022-06-30 |
DOP2022000104A (es) | 2022-07-31 |
CA3159055A1 (en) | 2021-05-27 |
MX2022006145A (es) | 2022-06-17 |
CN114667295B (zh) | 2024-03-29 |
EP4061842A1 (en) | 2022-09-28 |
KR20220084152A (ko) | 2022-06-21 |
AU2020387380A1 (en) | 2022-05-26 |
WO2021101823A1 (en) | 2021-05-27 |
CR20220228A (es) | 2022-06-08 |
JP7368624B2 (ja) | 2023-10-24 |
IL293018A (en) | 2022-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20075198A (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos | |
CO2022006708A2 (es) | Anticuerpos trem2 y usos de estos | |
CL2016002509A1 (es) | Composiciones para modular la expresión de sod-1 | |
GT201700188A (es) | Anticuerpos contra tau y sus usos | |
ECSP19020740A (es) | Anticuerpos anti-cd27 | |
NI201700019A (es) | Anticuerpos anti tigit | |
EA201890093A1 (ru) | Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина | |
CO2019012329A2 (es) | Polipéptidos que antagonizan la señalización wnt en células tumorales | |
CO2018003452A2 (es) | Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso | |
CL2017001135A1 (es) | Anticuerpos mejorados contra il-6 | |
DOP2018000040A (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
CL2019001043A1 (es) | Anticuerpos anti-il-33 y usos de los mismos. | |
EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
CL2016002281A1 (es) | Anticuerpos de il-21 | |
CL2018000611A1 (es) | Sales de un inhibidor de pim quinasa | |
CR20170247A (es) | 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
UY37980A (es) | Compuestos novedosos para tratar enfermedades parasitarias | |
MX2020009130A (es) | Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos. | |
CL2021001615A1 (es) | Anticuerpos anti il-36 y procedimientos de uso de estos | |
UY36081A (es) | Compuestos inhibidores de metaloenzima como fungicidas. | |
BR112022009493A2 (pt) | Fabricação de do3a protegido | |
BR112018005999A2 (pt) | métodos para a produção de intermediários de onapristona | |
BR112019025420A2 (pt) | Compostos policíclicos e usos destes | |
BR112022004475A2 (pt) | Proteínas de fusão nkg2d e usos das mesmas | |
EA201790428A1 (ru) | Синтез энт-прогестерона и его промежуточных соединений |